ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 374

Nailfold Microangiopathy in Dermatomyositis and Systemic Sclerosis: What Is Different?

Alberto Sulli1, Carmen Pizzorni1, Sabrina Paolino2, Giorgia Ferrari1, Veronica Tomatis1, Barbara Ruaro1, Vanessa Smith3 and Maurizio Cutolo1, 1Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, San Martino Polyclinic Hospital, Genoa, Italy, Genoa, Italy, 2Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, San Martino Polyclinic Hospital, Genoa, Italy, Genova, Italy, 3Department of Internal Medicine, Department of Rheumatology, Ghent University Hospital, Department of Internal Medicine, Ghent University, Ghent, Belgium, Ghent, Belgium

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Capillaroscopy, dermatomyositis and systemic sclerosis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 21, 2018

Title: Muscle Biology, Myositis and Myopathies Poster I: Clinical Features and Disease Course

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Nailfold videocapillaroscopy (NVC) is a non invasive and useful method to assess peripheral microvascular status and evaluate patients with connective tissue diseases (1). Microvascular involvement was clearly described in systemic sclerosis (SSc) (2-4), but may be detected also in patients with dermatomyositis (DM) (5,6). Only few studies described the main NVC changes over time in this last clinical condition (5,6). The aim of this retrospective study was to compare the NVC findings between DM and SSc at first NVC, and to identify NVC changes in patients with DM during a 3 year follow-up.

Methods: Twenty-four DM (mean age 54±15SD years; disease duration 4±5 years; 4 males and 20 females) and 24 SSc patients, matched for age and disease duration at first NVC were retrospectively evaluated. NVC was yearly performed by the same operator, and capillary parameters scored as reported in the literature (2-4). Clinical aspects and treatments were recorded. Non parametric test were used to carry out statistical analysis.

Results: Nineteen out of 24 DM patients (79%) showed a NVC “scleroderma-like pattern”. Comparing at baseline DM with SSc patients, the giant capillary and microhaemorrhage scores were significantly higher in SSc than in DM patients (1.42±0.58 vs 1.00±0.72, p=0.04, and 1.00±0.66 vs 0.67±0.56, p=0.05 respectively), while capillary density, ramification (abnormally shaped capillaries, expression of angiogenesis) and disorganization scores were higher in DM patients (1.54±0.72 vs 1.12±0.85, p=0.05; 1.79±1.02 vs 0.79±1.02, p=0.002; 1.67±0.82 vs 0.83±1.01, p=0.004, respectively). Accordingly, the absolute number of ramified capillaries was significantly higher in DM patients (1.92±1.06 vs 0.88±1.08, p=0.002), while the absolute capillary number was significantly higher in SSc patients (6.83±2.18 vs 5.62±1.95, p=0.05) at baseline. No statistically significant variations of all the capillaroscopic scores was observed during the 3 year follow-up in DM patients. By comparing DM patients with or without anti-Jo-1 antibody positivity, no statistically significant differences of the scores of the main capillary parameters was observed at baseline between the groups. However, anti-Jo-1 positive patients showed a statistically significant decrease of capillary ramifications at T2 (score 1.4±1.1 vs 2.6±0.7, p=0.05) and T3 (1.0±0.0 vs 2.6±0.5, p=0.03), when compared with the anti-Jo-1 negative group.

Conclusion: This study demonstrates that DM and SSc display different capillaroscopic features. The capillaroscopic manifestations of DM persist in contrast to the progressive changes described in SSc patients (4), and the anti-Jo-1 positivity do not seem to modify the DM NVC pattern.

References. 1.Cutolo M. et al. Best Pract Res Clin Rheumatol 2007;21:1093-108. 2.Cutolo M et al. Rheumatology 2004;43:719–26. 3.Sulli A et al. Ann Rheum Dis 2008;67:885-7. 4.Sulli A et al. Arthritis Rheum. 2012;64:821-5. 5.Bertolazzi C, et al. Semin Arthritis Rheum. 2017;47:432-444. 6.Manfredi A, et al. J Rheumatol. 2016;43:1575-80.


Disclosure: A. Sulli, None; C. Pizzorni, None; S. Paolino, None; G. Ferrari, None; V. Tomatis, None; B. Ruaro, None; V. Smith, None; M. Cutolo, None.

To cite this abstract in AMA style:

Sulli A, Pizzorni C, Paolino S, Ferrari G, Tomatis V, Ruaro B, Smith V, Cutolo M. Nailfold Microangiopathy in Dermatomyositis and Systemic Sclerosis: What Is Different? [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/nailfold-microangiopathy-in-dermatomyositis-and-systemic-sclerosis-what-is-different/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/nailfold-microangiopathy-in-dermatomyositis-and-systemic-sclerosis-what-is-different/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology